Biolife Sciences (BLFE) Stock Statistics & Valuation Metrics
Total Valuation
Biolife Sciences has a market cap or net worth of $4,829.00. The enterprise value is $311.53B.
- Market Cap
- $4,829.00
- Enterprise Value
- $311.53B
Share Statistics
Biolife Sciences has 4,829,364,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,829,364,000
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Biolife Sciences’s return on equity (ROE) is 1.84 and return on invested capital (ROIC) is 248.80%.
- Return on Equity (ROE)
- 1.84
- Return on Assets (ROA)
- -17.44
- Return on Invested Capital (ROIC)
- 248.80%
- Return on Capital Employed (ROCE)
- 1.80
- Revenue Per Employee
- 137.23K
- Profits Per Employee
- -422.67K
- Employee Count
- 3
- Asset Turnover
- 5.66
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Biolife Sciences is -0.00. Biolife Sciences’s PEG ratio is 0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.38
- PB Ratio
- -0.01
- Price to FCF
- -0.18
- Price to Operating Cash Flow
- -0.01
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Biolife Sciences had revenue of 411.69K and earned -1.27M in profits. Earnings per share was -0.02.
- Revenue
- 411.69K
- Gross Profit
- -985.00K
- Operating Income
- -1.24M
- Pretax Income
- -1.27M
- Net Income
- -1.27M
- EBITDA
- -1.22M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -49.93K and capital expenditures 0, giving a free cash flow of -49.93K billion.
- Operating Cash Flow
- -49.93K
- Free Cash Flow
- -49.93K
- Free Cash Flow per Share
- -0.02
Dividends & Yields
Biolife Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -565.01%
- Earnings Yield
- -24489.17%
Stock Price Statistics
- Beta
- -15.92
- 52-Week Price Change
- -99.49%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
Biolife Sciences as a current ratio of 0.09, with Debt / Equity ratio of -27.49%
- Current Ratio
- 0.09
- Quick Ratio
- 0.09
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.13
- Interest Coverage Ratio
- -25.22
Taxes
In the past 12 months, Biolife Sciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Biolife Sciences EV to EBITDA ratio is -0.26, with an EV/FCF ratio of -0.35.
- EV to Sales
- 0.76
- EV to EBITDA
- -0.26
- EV to Free Cash Flow
- -0.35
- EV to Operating Cash Flow
- -0.35
Balance Sheet
Biolife Sciences has $16.00 in cash and marketable securities with $398.00 in debt, giving a net cash position of -$382.00 billion.
- Cash & Marketable Securities
- $16.00
- Total Debt
- $398.00
- Net Cash
- -$382.00
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- $0.00
Margins
Gross margin is -239.25%, with operating margin of -302.17%, and net profit margin of -307.99%.
- Gross Margin
- -239.25%
- Operating Margin
- -302.17%
- Pretax Margin
- -307.99%
- Net Profit Margin
- -307.99%
- EBITDA Margin
- -295.95%
- EBIT Margin
- -295.85%
Analyst Forecast
The average price target for Biolife Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
